证券代码：603579 证券简称：荣泰健康 公告编号：2025-070 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 上海荣泰健康科技股份有限公司（以下简称"公司"）第四届董事会第二十 四次会议于 2025 年 9 月 29 日上午 10 时在上海市青浦区徐泾镇高光路 169 弄虹 桥时代广场荣泰大厦公司会议室以现场加通讯表决方式召开。会议通知和材料已 于 2025 年 9 月 23 日以现场送达、电话或电子邮件等方式发出。本次会议由董事 长林光荣先生主持，会议应参加董事 9 人，实际参加董事 9 人。公司监事及部分 高级管理人员列席了会议。本次会议的召集、召开程序符合《中华人民共和国公 司法》（以下简称"《公司法》"）等有关法律、法规、《上海荣泰健康科技股 份有限公司章程》（以下简称"《公司章程》"）的规定，会议决议合法、有效。 上海荣泰健康科技股份有限公司 第四届董事会第二十四次会议决议公告 二、董事会会议审议情况 1、审议通过《关于提名公司第五届董事会非独立董事候选人的议案》 根据有关法律、法规 ...

Group 1 - The other home appliance sector increased by 1.21% on September 29, with Rongtai Health leading the gains [1] - The Shanghai Composite Index closed at 3862.53, up 0.9%, while the Shenzhen Component Index closed at 13479.43, up 2.05% [1] - Key stocks in the other home appliance sector showed varied performance, with Rongtai Health closing at 35.35, up 1.41%, and Rongjie Health at 4.18, up 1.21% [1] Group 2 - The net outflow of main funds in the other home appliance sector was 14.61 million yuan, while retail investors saw a net inflow of 13.50 million yuan [1] - Specific stock fund flows indicated that Rongjie Health experienced a net outflow of 4.45 million yuan, while Aojiahua had a net outflow of 4.15 million yuan [1] - Rongtai Health had a significant net outflow of 14.31 million yuan, despite a slight increase in its stock price [1]

Core Insights - The event "Rongtai New Intelligent Manufacturing, New Paradigm of Health" showcased Rongtai's pragmatic approach and strong capabilities in the health technology sector [1] - Rongtai's General Manager Lin Qi emphasized the company's commitment to technology as the core driver of its competitive advantage and brand value [3][5] Technology and Innovation - Rongtai has invested 5% of its annual revenue into R&D, totaling approximately 721 million yuan over five years, resulting in 678 patented technologies [5] - The company has undergone six major technological iterations since its establishment in 1997, enhancing user experience through innovations in massage technology [6] - Rongtai's collaborations with leading universities and companies, such as Faurecia in ergonomic design and AR company XREAL, demonstrate its forward-looking ecological integration strategy [8] New Product Development - The introduction of the "massage robot" category reflects a shift in consumer health perspectives, focusing on personalized health management solutions [9] - The A70MAX massage robot exemplifies this innovation, offering active management of health through advanced features like the Bi-Stretch system [11][12] - The robot's intelligent voice interaction allows users to customize their experience, enhancing user engagement and satisfaction [13] Global Strategy and Market Positioning - Rongtai's dual strategy focuses on deepening its domestic market presence while expanding globally, aiming to elevate brand value and move away from price competition [17] - The company has established a comprehensive online and offline channel matrix, with nearly 1,000 stores and a strong presence on major e-commerce platforms [17] - The construction of a smart industrial park in Thailand marks a significant step in Rongtai's global supply chain strategy, enhancing responsiveness to Southeast Asian markets [19] Future Vision - Rongtai aims to transform from a product manufacturer to a comprehensive intelligent health platform, committed to improving the health and well-being of consumers [20] - The company envisions leveraging advanced technologies like brain-computer interfaces to create highly personalized health management experiences [15]

Core Viewpoint - Elon Musk emphasized that Tesla is fully committed to scaling the Optimus project, defining it as the most important product in the company's history, with expectations that it will account for 80% of the company's future value [2][6]. Group 1: Production Timeline and Goals - Tesla aims for internal limited production and testing of thousands of Optimus units by 2025, ramping up to 50,000-100,000 units for external sales in 2026, and targeting an annual production of 1 million units within five years [2]. - The current supply chain for Optimus is based on the design of Optimus V2, with actuators and sensors each accounting for approximately 30% of material costs [4]. Group 2: Supply Chain and Component Suppliers - The supply chain for Optimus includes Tier 1 suppliers such as Sanhua Intelligent Controls and Top Group for actuators, and Mingzhi Electric and Zhaowei Electromechanical for dexterous hands [7]. - Key component suppliers include Shuanghuan Transmission and Lide Harmony for reducers, Best for lead screws, and Rongtai Health for insulation parts [7]. - International Tier 1 suppliers include Amphenol for cables, TE Connectivity for six-dimensional torque sensors, and THK for lead screws [8]. Group 3: Challenges and Development Needs - Current challenges for Optimus include hardware issues such as overload and overheating of joint motors, insufficient dexterity and load capacity of dexterous hands, and the lifespan of transmission components [10]. - There is a need for improved compatibility between hardware and software, particularly in complex dynamic environments and multi-task coordination [10]. Group 4: Thermal Management Solutions - The thermal management system for Optimus V3 is similar to that of electric vehicles, focusing on the management of key components like batteries and motors [11]. - Sanhua Intelligent Controls is developing liquid cooling modules for Optimus, leveraging its experience in electric vehicle thermal management to address overheating issues in robotic joints [13]. - Sanhua plans to deliver approximately 2,000 actuators to Tesla by Q3 2025, with an annual order forecast of 5,000-10,000 units [13]. Group 5: Industry Trends and Future Outlook - Domestic suppliers are increasing investments to meet the demand for high-performance, miniaturized thermal management components for robots [14]. - The year 2025 is anticipated to be a pivotal year for humanoid robot mass production, with 2026 expected to be a critical turning point for the industry landscape [14]. - The upcoming iTherM 2025 conference will address advanced thermal management technologies and materials relevant to humanoid robots [15].

Market Overview - The other home appliance sector experienced a decline of 2.97% on September 26, with Rongtai Health leading the drop [1] - The Shanghai Composite Index closed at 3828.11, down 0.65%, while the Shenzhen Component Index closed at 13209.0, down 1.76% [1] Stock Performance - Rongtai Health (603579) closed at 34.86, down 5.76% with a trading volume of 83,700 shares and a transaction value of 296 million yuan [1] - Aojiahua (002614) closed at 6.62, up 0.61% with a trading volume of 76,100 shares [1] - Rongjie Health (300247) closed at 4.13, up 0.24% with a trading volume of 155,700 shares [1] Capital Flow - The other home appliance sector saw a net outflow of 2.5243 million yuan from main funds, while retail investors had a net inflow of 1.8336 million yuan [1] - Rongtai Health experienced a net outflow of 5.3050 million yuan, representing a decrease of 1.79% [1] - Aojiahua had a net outflow of 2.8473 million yuan, down 5.66% [1] - Rongjie Health faced a net outflow of 4.9288 million yuan, down 7.67% [1]

Group 1 - The other home appliance sector increased by 0.13% on September 25, with Rongtai Health leading the gains [1] - The Shanghai Composite Index closed at 3853.3, down 0.01%, while the Shenzhen Component Index closed at 13445.9, up 0.67% [1] - Rongtai Health's stock price rose by 1.87% to 66.96, with a trading volume of 75,700 shares and a transaction value of 282 million yuan [1] Group 2 - The net inflow of main funds in the other home appliance sector was 24.52 million yuan, while retail investors saw a net outflow of 30.30 million yuan [1] - Rongtai Health had a main fund net inflow of 38.72 million yuan, accounting for 13.74% of its trading volume, but experienced a retail net outflow of 32.01 million yuan, representing -11.36% [1] - Other companies like Aojiahua and Rongjie Health experienced mixed fund flows, with Aojiahua seeing a net inflow from speculative funds of 4.61 million yuan, while Rongjie Health had a significant net outflow from main funds of 12.43 million yuan [1]

Core Viewpoint - The global television panel shipment reached 22.3 million units in August 2025, showing a year-on-year increase of 7.6% and a month-on-month increase of 4.9%, indicating a recovery in inventory demand as brands prepare for the upcoming promotional season [1][2]. Group 1: Market Trends - The upcoming promotional season in overseas markets is expected to drive positive signals in panel procurement, with brands actively stocking up for events like Black Friday and Christmas [1]. - The global MiniLED television penetration rate is projected to reach 6.6% by 2025, with Chinese brands leading the push for MiniLED technology while Korean companies focus on OLED [2][3]. Group 2: Competitive Landscape - Chinese brands are significantly increasing their global market share in the television sector, with Hisense's share rising from 6.2% in 2016 to 14.4% in 2025, and TCL's share increasing from 5.8% to 14.8% during the same period [2]. - Samsung's TV business is undergoing a comprehensive review for the first time since 2015 due to competitive pressure from Chinese brands leveraging MiniLED technology [2]. Group 3: Technological Advancements - Chinese companies are leading the upgrade in MiniLED technology, with Hisense launching the RGB MiniLED TV UX series and TCL introducing the world's first SOD MiniLED flagship product, X11L [3]. - The shift in technological leadership marks a significant change, with Japanese and Korean companies now following the advancements made by Chinese firms in the MiniLED space [3]. Group 4: Retail Performance - Retail sales of televisions in China have begun to decline due to the reduction of government subsidies, with online retail sales growth dropping to -34.7% and -30.5% in the first two weeks of September [4]. - The decline in retail performance is attributed to the high year-on-year comparison and the impact of subsidy reductions starting from September 2024 [4].

Group 1 - The core viewpoint of the news is that Rongtai Health's stock has seen a 5% increase, reaching 36.72 CNY per share, with a trading volume of 112 million CNY and a turnover rate of 1.55%, resulting in a total market capitalization of 7.467 billion CNY [1] - Rongtai Health, established on November 15, 2002, and listed on January 11, 2017, specializes in the design, research and development, production, and sales of massage equipment [1] - The main revenue composition of Rongtai Health includes massage chairs at 96.12%, small massage appliances at 2.59%, other supplementary services at 1.00%, and experiential massage services at 0.29% [1] Group 2 - Among the top ten circulating shareholders of Rongtai Health, a fund under the Fortune Fund ranks first, with the Fortune Emerging Industries Stock A/B fund newly entering the top ten shareholders, holding 2.5575 million shares, which accounts for 1.44% of the circulating shares [2] - The Fortune Emerging Industries Stock A/B fund, established on March 12, 2015, has a latest scale of 3.137 billion CNY, with a year-to-date return of 69.9%, ranking 116 out of 4220 in its category; over the past year, it has achieved a return of 164.09%, ranking 28 out of 3814; and since its inception, it has returned 278.7% [2] Group 3 - The fund manager of the Fortune Emerging Industries Stock A/B fund is Sun Quan, who has been in the position for 3 years and 210 days, managing a total fund asset size of 7.75 billion CNY, with the best fund return during his tenure being 111.87% and the worst being 35.44% [3]

Group 1 - The A-share market saw a significant decline in brain-computer interface concept stocks, with several companies experiencing drops of over 5% [1] - Notable companies that fell over 5% include Dineike, Xiangyu Medical, Meihao Medical, Chengdu Huamei, and Tom Cat [1] - Other companies such as Yanshan Technology, Zhongke Information, Aipeng Medical, Nanjing Panda, Weisi Medical, Innovation Medical, Robot, Mailande, Beiqingsong, Botuo Biological, and Rongtai Health dropped over 4% [1]

Group 1 - Rongtai Health's stock price fell by 5.15% on September 23, closing at 34.78 CNY per share, with a trading volume of 153 million CNY and a turnover rate of 2.13%, resulting in a total market capitalization of 7.073 billion CNY [1] - The stock has experienced a continuous decline over three days, with a cumulative drop of 8.32% during this period [1] - The company, Shanghai Rongtai Health Technology Co., Ltd., was established on November 15, 2002, and went public on January 11, 2017, primarily engaged in the design, research and development, production, and sales of massage equipment [1] Group 2 - The main revenue composition of Rongtai Health includes massage chairs (96.12%), small massage appliances (2.59%), other supplementary products (1.00%), and experiential massage services (0.29%) [1] - Among the top ten circulating shareholders, a fund under the Fortune Fund, specifically Fortune Emerging Industries Stock A/B (001048), entered the top ten in the second quarter, holding 2.5575 million shares, which accounts for 1.44% of the circulating shares [2] - The estimated floating loss for the fund today is approximately 4.8336 million CNY, with a total floating loss of 8.5164 million CNY during the three-day decline [2] Group 3 - Fortune Emerging Industries Stock A/B (001048) was established on March 12, 2015, and has a current scale of 3.137 billion CNY, with a year-to-date return of 70.57%, ranking 108 out of 4220 in its category [2] - The fund has achieved a one-year return of 163.48%, ranking 20 out of 3814 in its category, and a cumulative return of 280.2% since inception [2] - The fund manager, Sun Quan, has been in position for 3 years and 209 days, with the fund's total asset size at 7.75 billion CNY, achieving the best return of 105.39% and the worst return of 34.81% during his tenure [3]